Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab

Marijke Stryckers; Stefaan Van Oevelen; Priyanka Koshy; Ben Sprangers; Amaryllis H Van Craenenbroeck

doi:10.1093/ckj/sfad161

Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab

Clin Kidney J. 2023 Jul 6;16(10):1701-1702. doi: 10.1093/ckj/sfad161. eCollection 2023 Oct.

Authors

Marijke Stryckers¹, Stefaan Van Oevelen¹, Priyanka Koshy², Ben Sprangers^{3

4}, Amaryllis H Van Craenenbroeck^{5

6}

Affiliations

¹ Department of Nephrology, H. Hart-Ziekenhuis, Lier, Belgium.
² Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Nephrology, Ziekenhuis Oost-Limburg, Genk, Belgium.
⁴ Department of Immunology and Infection, Biomedical Research Institute of the Hasselt University, Diepenbeek, Belgium.
⁵ Department of Microbiology and Immunology, Laboratory of Nephrology of the KU Leuven, LeuvenBelgium.
⁶ Department of Neprology, University Hospitals Leuven, Leuven, Belgium.

Abstract

We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after cessation of the drug without relapse (2 years of follow-up). To the best of our knowledge, this is the first case describing FSGS lesions associated with the use of an interleukin-23 inhibitor.

Keywords: IL-23; focal segmental glomerulosclerosis; guselkumab.

Publication types

Case Reports